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Abstract
Background: Cochlear outer hair cells change their length in response to variations in membrane potential. This
capability, called electromotility, is believed to enable the sensitivity and frequency selectivity of the mammalian
cochlea. Prestin is a transmembrane protein required for electromotility. Homozygous prestin knockout mice are
profoundly hearing impaired. In humans, a single nucleotide change in SLC26A5, encoding prestin, has been
reported in association with hearing loss. This DNA sequence variation, IVS2-2A>G, occurs in the exon 3 splice
acceptor site and is expected to abolish splicing of exon 3.
Methods: To further explore the relationship between hearing loss and the IVS2-2A>G transition, and assess
allele frequency, genomic DNA from hearing impaired and control subjects was analyzed by DNA sequencing.
SLC26A5 genomic DNA sequences from human, chimp, rat, mouse, zebrafish and fruit fly were aligned and
compared for evolutionary conservation of the exon 3 splice acceptor site. Alternative splice acceptor sites within
intron 2 of human SLC26A5 were sought using a splice site prediction program from the Berkeley Drosophila
Genome Project.
Results: The IVS2-2A>G variant was found in a heterozygous state in 4 of 74 hearing impaired subjects of
Hispanic, Caucasian or uncertain ethnicity and 4 of 150 Hispanic or Caucasian controls (p = 0.45). The IVS2-2A>G
variant was not found in 106 subjects of Asian or African American descent. No homozygous subjects were
identified (n = 330). Sequence alignment of SLC26A5 orthologs demonstrated that the A nucleotide at position
IVS2-2 is invariant among several eukaryotic species. Sequence analysis also revealed five potential alternative
splice acceptor sites in intron 2 of human SLC26A5.
Conclusion: These data suggest that the IVS2-2A>G variant may not occur more frequently in hearing impaired
subjects than in controls. The identification of five potential alternative splice acceptor sites in intron 2 of human
SLC26A5 suggests a potential mechanism by which expression of prestin might be maintained in cells carrying the
SLC26A5 IVS2-2A>G DNA sequence variation. Additional studies are needed to evaluate the effect of the IVS2-
2A>G transition on splicing of SLC26A5 transcripts and characterize the hearing status of individuals homozygous
for the IVS2-2A>G variant.
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Background
Outer hair cells (OHCs) are sensory cells of the mamma-
lian cochlea. These cells are cylindrical in shape, with ster-
eocilia projecting from their apical surfaces and neuronal
synapses associated with their basal surfaces. Mechanical
deflection of OHC stereocilia, in response to sound pres-
sure waves, results in variations in the OHC membrane
potential that trigger somatic cell length changes in syn-
chrony with the sound wave. Hyperpolarizing potentials
elongate the cell and depolarizing potentials shorten the
cell. Known as electromotility, this capability is believed
to amplify cochlear vibrations and enable the acute hear-
ing sensitivity and frequency selectivity of the mammalian
cochlea [1-3].
Prestin is a multipass transmembrane protein of the OHC
required for electromotility [2,3]. Developmental expres-
sion of prestin coincides with the appearance of electro-
motility [4]. When prestin is expressed in non-auditory
mammalian cells in vitro, a non-linear, voltage-dependent
membrane capacitance, a commonly used marker of elec-
tromotility, results [3,5]. Targeted deletion of prestin in
mice eliminates OHC electromotility and results in a sig-
nificant (40-60dB) loss of cochlear sensitivity and an
increased high frequency hearing threshold [3,6,7]. The
human gene SLC26A5, encoding prestin, contains 21
exons that are alternately spliced to create four isoforms of
prestin with variable lengths of the C-terminus [8]. The
expression profile of the four isoforms in OHCs and their
significance with respect to electromotility are not known
[8].
In humans, a single nucleotide change in the second
intron of SLC26A5 has been reported in association with
hearing loss [8]. The DNA sequence variation, IVS2-2A>G,
is an A to G transition in the splice acceptor site for exon
3. The A nucleotide at position IVS2-2 of SLC26A5 was
found to be conserved in human, mouse, and rat
orthologs and mutation of this nucleotide is predicted to
cause skipping of exon 3 [8-10]. The start codon for the
prestin protein is encoded in exon 3 of SLC26A5 [8,10].
Skipping of exon 3 during RNA processing would be
expected to result in a messenger RNA incapable of prestin
protein production and cochlear hearing loss due to
absence of OHC electromotility [8-10].
To further explore the relationship between the SLC26A5
IVS2-2A>G nucleotide substitution and hearing loss, and
assess allele frequency, genomic DNA from hearing
impaired and control subjects was genotyped at the
SLC26A5  IVS2-2 position. In addition, SLC26A5
orthologs from various eukaryotic species were evaluated
for conservation of the A nucleotide at position IVS2-2.
An attempt was also made to identify possible alternative
splice acceptor sites within intron 2 that might support
alternate splicing of exon 3.
Methods
Subjects
Hearing impaired patients were identified and recruited
from the outpatient clinical care centers of the Bobby R.
Alford Department of Otorhinolaryngology and Commu-
nicative Sciences and the Department of Molecular and
Human Genetics of Baylor College of Medicine. Ethnicity
of cases was self-described. Control specimens were
obtained from the Baylor Polymorphism Resource http://
www.cardiogene.org. In this resource, Caucasian subjects
were European Americans. Ethnicity of controls was
recorded by the Baylor Polymorphism Resource group at
the time of specimen collection. The hearing status of con-
trols is unknown however the process through which con-
trol subjects were recruited included verbal
communication, reducing the likelihood that individuals
with significant hearing impairment were unknowingly
included in the control population.
IRB approval
This work was approved by the Baylor College of Medi-
cine Institutional Review Board. Informed consent was
obtained and documented from all subjects prior to spec-
imen collection.
Specimen collection
Blood was collected from all subjects by peripheral veni-
puncture. Lymphoblastoid cell lines were established by
standard Epstein Barr Virus mediated transformation
protocols.
DNA isolation
DNA was isolated from cultured cells using the PURE-
GENE® DNA Purification Kit for cells (Gentra Systems,
Inc., Minneapolis, Minnesota, USA), according to manu-
facturer's specifications.
Sequencing of the SLC26A5 exon 3 splice acceptor site
The region surrounding the exon 3 splice acceptor site of
SLC26A5 was amplified from human genomic DNA by
polymerase chain reaction (PCR) using the forward
primer Prestin-5'F from [8] and, a reverse primer that was
derived from primer Prestin-4R from [8] by the addition
of 5 nucleotides to the 5' end as follows, 5'-GCAATTGTTT-
GAGGACAGCAAGGG-3'. PCR was conducted with 15
pmol of each primer, 1.25U Taq DNA polymerase (Amer-
sham Pharmacia Biotech Inc., Piscataway, NJ, USA), and
1 × PCR buffer, as provided by the manufacturer, in a total
volume of 25 µL. PCR was conducted as follows: 94°C for
2 minutes; 40 cycles of 94°C for 30 seconds, 58°C for 30
seconds, and 70°C for 1 minute; and, 70°C for 5 minutes.
PCR fragments were sequenced using the forward primerBMC Medical Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2350/6/30
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and the ABI BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems Inc, Foster City, California, USA).
Cycle sequencing was conducted as follows: 25 cycles of
96°C for 10 seconds; 50°C for 5 seconds; and, 60°C for 4
minutes. Sequencing reactions were analyzed on an ABI
Prism 310 Genetic Analyzer according to the manufac-
turer's specifications (Applied Biosystems, Foster City,
CA).
Sequencing of the coding regions of GJB2 (Connexin 26) 
and GJB6 (Connexin 30)
The coding region of GJB2  was amplified by PCR and
sequenced using the following primers: forward PCR
primer, 5'-AGGAAGAGATTTAAGCATGCT-3'; reverse PCR
primer, 5'-TGGAGTTTCACCTGAGGC-3'; forward
sequencing primer, 5'-CTGCAGCTGATCTTCGTG-3'; and,
reverse sequencing primer, 5'-GTCGTACATGACATAGAA-
GACGT-3'. The coding region of GJB6 was amplified from
human genomic DNA by PCR using the following prim-
ers: forward PCR primer derived from primer Cx30-1 from
[11] by the addition of 3 nucleotides to the 5' end and the
removal of 2 nucleotides from the 3' end as follows, 5'-
GACTCAGGGATAAACCAGCGCA-3'; reverse PCR and
sequencing primer Cx30-8 from [11], and reverse
sequencing primer Cx30-4 from [11]. PCR and sequenc-
ing were conducted as described for the SLC26A5 exon 3
splice acceptor site.
GJB6 (Connexin 30) deletion analysis
The GJB6 gene was evaluated for the 342 kilobase pair
deletion shown to be associated with hearing loss as
described [11-13].
Mitochondrial 12S rRNA gene sequencing and restriction 
analysis for the 1555A>G mutation
DNA samples were amplified by PCR using primers
derived from MITOMAP and PCR conditions as previ-
ously described [14,15]. The presence of the 1555A>G
mutation was evaluated in some subjects by DNA
sequencing as previously described [15] and in other sub-
jects by restriction digestion using BsmAI (New England
BioLabs, Beverly, MA, USA) according to manufacturer's
specifications and as described [16].
Sequence analysis
Electropherograms were evaluated by visual inspection
and pairwise alignment to reference sequences using the
BCM Search Launcher BLAST2 Pairwise Sequence Align-
ment Tool from the Human Genome Sequencing Center
of Baylor College of Medicine http://search
launcher.bcm.tmc.edu/seq-search/alignment.html, and/
or by interpretation using Mutation Surveyor software
Version 2.41 (Softgenetics, Inc, State College, Pennsylva-
nia, USA).
Statistical analysis
Fisher's exact test of 2 × 2 contingency tables was used to
calculate the two-tailed p values associated with allele fre-
quencies in case and control groups. Fisher's exact test was
performed using the GraphPad QuickCalcs Online Calcu-
lator for Scientists http://www.graphpad.com/quickcalcs/
index.cfm.
Multiple sequence alignment of the exon 3 splice acceptor 
site of SLC26A5
SLC26A5 genomic DNA sequences from human, chimp,
rat, mouse, zebrafish and fruit fly were obtained from the
Ensembl Genome Browser http://www.ensembl.org. Pres-
tin sequences at the intron 2 and exon 3 junction were
compared using ClustalW multiple sequence alignment
tool, Biology WorkBench 3.2 http://seqtool.sdsc.edu/
CGI/BW.cgi#!.
Evaluation of potential alternative splice acceptor sites 
within intron 2 of human SLC26A5
Alternative splice acceptor sites within intron 2 of human
SLC26A5 were sought using a splice site prediction pro-
gram from the Berkeley Drosophila Genome Project http:/
/www.fruitfly.org/seq_tools/splice.html. Only sites hav-
ing a confidence score above 0.99 out of a maximum pos-
sible score of 1.00 were considered to be potential
alternative splice sites.
Results
Allele frequency of the IVS2-2A>G DNA sequence variation
Eighty-four hearing impaired cases and 246 controls were
genotyped for the exon 3 splice acceptor site of SLC26A5,
encoding prestin. Four hearing impaired cases were found
to be heterozygous for the IVS2-2A>G nucleotide substitu-
tion: one Hispanic, two Caucasian, and one of uncertain
ethnicity, possibly Caucasian or mixed Caucasian. Four
controls were also found to be heterozygous for the IVS2-
2A>G nucleotide substitution: one Hispanic and three
Caucasian (Table 1). Four of the eight carriers were male:
three cases and one control. Four of the eight carriers were
female: three controls and one case. The IVS2-2A>G
nucleotide substitution was not found in 106 subjects of
Asian or African American descent nor was it found in a
homozygous state in any of 330 total subjects (Table 1).
Data from the control population suggests an allele fre-
quency for the IVS2-2A>G nucleotide substitution of
approximately 0.007 in Hispanics (carrier frequency
1.3%) and 0.02 in European American Caucasians (carrier
frequency 4%). The difference in allele frequency of the
IVS2-2A>G nucleotide substitution between cases and
controls was evaluated by derivation of two-tailed p val-
ues using Fisher's exact test of 2 × 2 contingency tables.
The difference in allele frequency of the IVS2-2A>G vari-
ant between cases and controls among Hispanics andBMC Medical Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2350/6/30
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Caucasians in this population was not statistically signifi-
cant (p = 0.45). If Asian and African American cases and
controls are included in the Fisher's exact test analysis, the
allele frequency distribution still does not reach statistical
significance (p = 0.12, Table 1).
The phenotype and audiometric profile of each of the four
hearing impaired subjects who were carriers of the
SLC26A5 IVS2-2A>G nucleotide substitution was unique
(Table 2). Of note, the hearing impaired sibling of case #4
did not carry the IVS2-2A>G DNA sequence variation.
Among the four SLC26A5 IVS2-2A>G carriers, hearing loss
associated mutations were not found in the coding
regions of GJB2 or GJB6, encoding Connexin 26 and Con-
nexin 30 respectively. The deletion mutation in GJB6 [11-
13] and the 1555A>G mutation in the mitochondrial 12S
Table 1: Genotypes of cases and controls at position SLC26A5 IVS2-2.
Ethnicity Case Genotypes Control Genotypes Fisher's exact test two-tailed p value
A/A A/G A/A A/G
Hispanic 22 1 75 1 p = 0.41 p = 0.45
Caucasian 34 2 71 3 p = 0.66
Uncertain (Caucasian/Mixed Caucasian) 14 1 0 0 Not Done
Asian 3 0 50 0 Not Done
African American 7 0 46 0 Not Done
Total 80 4 242 4 p = 0.12
Table 2: Phenotypes of hearing impaired carriers of SLC26A5 IVS2-2A>G.
Case Type of Hearing Loss; 
Age at onset
Associated Anomalies Family History Ethnicity GJB2, GJB6, 12S rRNA
1 Profound sensorineural 
on right, severe 
conductive on left; 
Congenital
Internal auditory canal 
hypoplasia, hypoplastic 
vestibulocochlear nerve 
on right; External 
auditory canal atresia, 
malformed ossicles on 
left
None reported Hispanic Heterozygous GJB2 V27I 
polymorphism, no 
mutations or other 
variants found
2 Severe to profound on 
right, moderate to severe 
on left, mixed, 
progressive; Early 
childhood, sudden, with 
head trauma and ear 
infection
Bilateral enlarged 
vestibular aqueducts; 
Disequilibrium; History 
of ear infections and 
possible meningitis
None reported Caucasian No mutations or variants 
found
3 Moderate to severe, 
bilateral, sloping 
audiogram, sensorineural, 
progressive; Childhood 
to young adulthood
None Consistent with 
autosomal dominant 
inheritance
Caucasian No mutations or variants 
found
4 Moderate on right, mild 
to moderate on left, 
sensorineural, 
progressive; Childhood
None Hearing impaired sibling 
(progressive, mild on 
right, mild to moderate 
on left, sensorineural; 
childhood onset; renal 
malformation); hearing 
impaired grandparent 
(unknown severity, 
possibly noise-induced)
Uncertain: Caucasian/
Mixed Caucasian
No mutations or variants 
foundBMC Medical Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2350/6/30
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rRNA gene [16-18] were also absent from these hearing
impaired  SLC26A5  IVS2-2A>G carriers. Neither genetic
nor hearing tests were performed on the parents or other
relatives of these subjects.
Multiple sequence alignment of the exon 3 splice acceptor 
site of SLC26A5
SLC26A5 genomic DNA sequences from human, chimp,
rat, mouse, zebrafish and fruit fly were aligned and com-
pared for evolutionary conservation of the exon 3 splice
acceptor site and, in particular, the AG dinucleotide. The
A and G nucleotides at positions -2 and -1, respectively, of
the exon 3 splice acceptor site were invariably present and
evolutionarily conserved among all eukaryotic prestin
orthologs analyzed (Table 3).
Evaluation of alternative splice sites within intron 2 of 
SLC26A5
To identify possible alternative splice acceptor sites within
intron 2 of SLC26A5 that might support alternate splicing
of exon 3, the 21,515 base pair genomic DNA sequence of
intron 2 was analyzed using a splice site prediction pro-
gram from the Berkeley Drosophila Genome Project http:/
/www.fruitfly.org/seq_tools/splice.html. Five alternative
splice acceptor sites demonstrating a confidence score
greater than 0.99 out of a maximum of 1.00 were identi-
fied within intron 2 of SLC26A5 (Figure 1).
Discussion
These data suggest that heterozygosity for the SLC26A5
IVS2-2A>G DNA sequence variation may not be, by itself,
sufficient to cause hearing loss. Only one of the four hear-
ing impaired carriers of the SLC26A5 IVS2-2A>G DNA
sequence variation identified in this study reported a his-
tory of hearing loss in a parent. Further, various additional
clinical findings in each of the hearing impaired carriers of
the SLC26A5 IVS2-2A>G variant argue against SLC26A5
being the cause of hearing loss in each of these cases
(Table 2).
The carrier frequency for the SLC26A5 IVS2-2A>G DNA
sequence variation in the control populations used in this
study was observed to be 1.3% in Hispanics and 4% in
Caucasians. These data suggest that the SLC26A5 IVS2-
Table 3: Multiple sequence alignment of the exon 3 splice acceptor site of SLC26A5.
Species Intron 2/EXON 3* Ensembl Gene ID
Human cccctag/TGACACT ENSG00000170615
Chimp cccctag/TGACACT ENSPTRG00000019554
Rat cctgcag/GCTTAGC ENSRNOG00000011616
Mouse cccttag/TGGCCAT ENSMUSG00000029015
Zebrafish ttttcag/CTGTTCG ENSDARG00000022424
Fruit fly ttttcag/CTCCTAA CG5485
*The invariant AG dinucleotide at the intron 2/exon 3 splice acceptor site is shown in bold and underlined.
Potential alternate splicing of intron 2 of SLC26A5 containing the IVS2-2A>G variant Figure 1
Potential alternate splicing of intron 2 of SLC26A5 containing the IVS2-2A>G variant. Alternative splice acceptor 
sites in intron 2 of SLC26A5 having a confidence score above 0.99 out of a maximum possible score of 1.00 are shown. Num-
bering of intron 2 begins at the +1 position. Dotted lines above the gene drawing show potential alternately spliced gene prod-
ucts. The solid line below the gene drawing shows the wild type splice donor and acceptor sites that join exon 2 to exon 3.BMC Medical Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2350/6/30
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2A>G DNA sequence variation may not be uncommon
and that it occurs in multiple ethnic groups, in contrast to
previous studies [8]. The SLC26A5  IVS2-2A>G DNA
sequence variation was not found in Asians or African
Americans. This observation may reflect absence of the
variant in these ethnic groups or may be due to the small
size of the study population.
Although nothing is known about the hearing status of
the control group, the allele frequency of the SLC26A5
IVS2-2A>G variant was not significantly different between
cases and controls. In addition, the SLC26A5 IVS2-2A>G
variant was not found in homozygosity in any hearing
impaired case. Given the high allele frequency of the IVS2-
2A>G variant in the Caucasian and Hispanic control pop-
ulations, if this variant were associated with hearing loss,
it is reasonable to expect that homozygous hearing
impaired cases would have been observed in the study
group. This expectation is based on the following observa-
tions. First, congenital genetic hearing loss affects, con-
servatively, approximately 1 in 2,000 live births in the
United States [19]. A carrier rate in Caucasians of 4% for
the SLC26A5 IVS2-2A>G nucleotide substitution suggests
that approximately 1 in 2,500 Caucasians should be
homozygous for this mutation. If this DNA sequence var-
iation were related to hearing loss, it should account for a
large percentage of cases of early onset genetic hearing loss
in Caucasians. Curiously, SLC26A5 has not been mapped
by traditional linkage analysis in any of the families with
hereditary hearing loss that have so far been studied
worldwide (Van Camp G, Smith RJH. Hereditary Hearing
Loss Homepage. http://webhost.ua.ac.be/hhh. Further,
the carrier rate among Caucasians for mutations in GJB2,
encoding Connexin 26, widely believed to be the most
common cause of early onset genetic hearing loss in the
United States, is estimated to be approximately 3% [20].
This is 1% less than the carrier frequency of the SLC26A5
IVS2-2A>G DNA sequence variation observed among
Caucasians in this study. The common 35delG mutation
in GJB2 is, by itself, estimated to have a carrier rate in US
Caucasians of approximately 2.5% [20]. In a group of 94
hearing impaired cases that includes the 84 subjects tested
in this study for SLC26A5  IVS2-2A>G, five subjects
homozygous for the 35delG mutation were found
(unpublished observation). In contrast, no subjects
homozygous for the IVS2-2A>G DNA sequence variation
were observed. These observations challenge whether the
SLC26A5 IVS2-2A>G DNA sequence variation is associ-
ated with hearing loss.
As shown in Table 3, the AG dinucleotide at the splice
acceptor site of exon 3 of SLC26A5 is invariant and evolu-
tionarily conserved amongst prestin orthologs. Analysis of
gene structure in multiple species including vertebrates,
invertebrates, plants and viruses suggested that the AG
dinucleotide of 3' splice acceptor sites cannot tolerate
mutation [9]. Thus, the IVS2-2A>G substitution creates a
sequence variation in SLC26A5 that is expected to cause
skipping of exon 3 [8,9]. However, since a number of
potential alternative splice acceptor sites exist within
intron 2 of human SLC26A5 (Figure 1), and the transla-
tion start codon for prestin is found within exon 3 [8,10],
alternate splicing of exon 3 within intron 2 might be com-
patible with production of a correctly translated prestin
protein. Alternatively, utilization of one or more alternate
splice sites in a way that minimizes the number of tran-
scripts missing exon 3 during functional maturation of the
cochlea might minimally impact the level of prestin in
mature OHCs. This hypothesis requires in vivo evaluation
of splicing and steady state protein levels in cells carrying
SLC26A5 genes with the IVS2-2A>G substitution, and in
particular during functional maturation of the cochlea.
Further studies are needed to clarify and refine the IVS2-
2A/G allele frequencies in various ethnic groups and
examine the role of the IVS2-2A>G nucleotide substitu-
tion in hearing loss. These studies should include screen-
ing of additional case and control populations for the
SLC26A5 IVS2-2A>G DNA sequence variation, and iden-
tification and audiometric testing of carriers and
homozygous individuals.
Conclusion
The exon 3 splice acceptor sequence of SLC26A5 is evolu-
tionarily conserved. Disruption of the canonical AG dinu-
cleotide at this splice acceptor site by the IVS2-2A>G
transition is expected to abolish splice site recognition
and result in skipping of exon 3. The IVS2-2A>G transi-
tion is found in individuals of Hispanic and European
American (Caucasian) ancestry, suggesting this DNA
sequence variation is not limited to a single ethnic group.
Among Hispanics and Caucasians, there is no statistically
significant difference in allele frequency of the IVS2-2A>G
nucleotide substitution between hearing impaired cases
and controls, challenging whether this DNA sequence var-
iation is associated with hearing loss. The detection of
alternative splice acceptor sites within intron 2 suggests a
potential mechanism by which expression of prestin
might be maintained in cells carrying the SLC26A5 IVS2-
2A>G DNA sequence variation. Further studies of the
SLC26A5 IVS2-2A>G DNA sequence variation are needed.
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